Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Energy & mining recover to lift TSX
Following a nasty session in the red, Canada’s main stock index rose more than 300 points in Friday trading. Gains were led by the energy and base metal sectors.After two brutal weeks brought... read article.
The Cannabis Report: June 24, 2022
Nextleaf to launch THC-O as an excise tax-free alternative to Delta-9-THC Nextleaf Solutions (OILS) has provided an update on the manufacturing of D9-tetrahydrocannabinol acetate,... read article.
Buzz on the Bullboards: Another summer of uncertainty?
In times of uncertainty in the markets, investors tend to focus on more consistent plays.Not all investors are basking in summer vacations and backyard barbeques. For those who are still plugged... read article.

NO PLI, TIME TO CHANGE NAME AGAIN

TO BIO CRA P.  rate and reply

SIMPLE QUESTION LMNL BOARD, LIVE IN A RUSSIA JAIL OR

GO FIGHT AGAINST THEM ? I BET YOU WOULD SIT IN JAIL...  rate and reply

PUTIN WILL SHOOT YOU,

WHY NOT, YOUR CRIMINALS...  rate and reply

ANNUAL GENERAL MEETING OF SHARHOLDERS....

ALL VOTED TO SEND MANAGMENT TO RUSSIA, THEY CAN INVEST IN YOU THERE.  rate and reply

GOOD NEWS!

CEO FOUND HIS CAR KEYS IN THE BAR, NOT IN HER BED!  rate and reply

New Press Release - Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England, June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6, 2022. A total of 20,209,035 common shares...read article.

YUP, MAKE WORK PROJECT FROM QUEBEC.

THIS ONE IS OVER, FOLKS. FIND YOUR A SS AGAIN...  rate and reply

WHAT???

Seriously?   Can't believe my eyes.   Still apparently there are some folks "invested" in this disgust. Thanks God, not always wrong, out of this disgusting dirty...read more

court proceedings

haven't heard anything about the court proceedings in months now,  is it dead yet? Still paying the lawyers?  rate and reply

crappot, you have unread messages in your inbox

if you prefer them in english, let me know  rate and reply

New study will probably not continue past phase 1-2

They sold plasma division for peanuts few weeks before fda approved our drug   prometic had excellent results re 4050 in more than one study  and they stopped studies after they wiped out...read more

New Press Release - Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

LAVAL, QC and CAMBRIDGE, England, May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD") randomized, open label, cross over clinical...read article.

RE:RE:New Wave Count?

The company has momentum.  The CEO   Bruce P  says so: "We expect to continue building on this momentum for the remainder of 2022." More like a steamroller speeding...read more

RE:New Wave Count?

Still pumping this turd I see. From $15 to 0.50, when will you figure out their intentions? You going to hold till there's nothing left? Its coming, been telling you for years!!    rate and reply

RE:New Wave Count?

Valued fairly now and will just bleed slowly until they get close to bankruptcy. There is no real interest by Thomvest to run this business.      rate and reply

New Wave Count?

LMNL have $60 M cash...$20 M market cap....? Undervalued....? Biotech ETF's...all time lowss...LABU topped $150, today $5....wow. Sodium Phenylbutyrate....hyper ammonia....$1B market...?  rate and reply

Liminal BioSciences Reports Q1 2022 - Bagel, Nada, Crapola

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence...read more

Market Cap

2 billions to 20 Millions in 5 years  rate and reply

RE:Stickyscamo

Thanks PLITheone for your warnings  rate and reply

When they killed all 5 4050 fibrosis indications…

They appear to have nothing left after killing all of the positive 4050 results or that is the perception that they want to project and are winding this down.    rate and reply
The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >